Platelet signaling-A primer

Journal of Veterinary Emergency and Critical Care

Volumn 22, Issue 1, 2012, Pages 5-29

  Goggs, Robert ^a   Poole, Alastair W ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Aggregation; Integrin; Primary hemostasis; Thrombus

Indexed keywords

CELL SURFACE RECEPTOR;

ANIMAL; BLOOD CLOTTING; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION;

ANIMALS; BLOOD COAGULATION; BLOOD PLATELETS; PLATELET ACTIVATION; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION;

EID: 84863863847     PISSN: 14793261     EISSN: 14764431     Source Type: Journal    
DOI: 10.1111/j.1476-4431.2011.00704.x     Document Type: Review

References (339)

1. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemostasis 2001; 85(6):958-965.
2. Boudreaux MK. Characteristics, diagnosis, and treatment of inherited platelet disorders in mammals. J Am Vet Med Assoc 2008; 233(8):1251-1259.
3. Boudreaux MK, Catalfamo JL, Klok M. Calcium-diacylglycerol guanine nucleotide exchange factor I gene mutations associated with loss of function in canine platelets. Transl Res 2007; 150(2):81-92.
4. Flatland B, Fry MM, Baek SJ, et al. May-Hegglin anomaly in a dog. Vet Clin Pathol 2011; 40(2):207-214.
5. Boudreaux MK, Martin M. P2Y12 receptor gene mutation associated with postoperative hemorrhage in a Greater Swiss Mountain dog. Vet Clin Pathol 2011; 40(2):202-206.
6. Boudreaux MK, Kvam K, Dillon AR, et al. Type I Glanzmann's thrombasthenia in a Great Pyrenees dog. Vet Pathol 1996; 33(5):503-511.
7. Lipscomb DL, Bourne C, Boudreaux MK. Two genetic defects in alphaIIb are associated with type I Glanzmann's thrombasthenia in a Great Pyrenees dog: a 14-base insertion in exon 13 and a splicing defect of intron 13. Vet Pathol 2000; 37(6):581-588.
8. Boudreaux MK, Catalfamo JL. Molecular and genetic basis for thrombasthenic thrombopathia in otterhounds. Am J Vet Res 2001; 62(11):1797-1804.
9. Johnstone IB, Lotz F. An inherited platelet function defect in Basset hounds. Can Vet J 1979; 20(8):211-215.
10. Boudreaux MK, Crager C, Dillon AR, et al. Identification of an intrinsic platelet function defect in Spitz dogs. J Vet Intern Med 1994; 8(2):93-98.
11. Lothrop CD, Jr., Candler RV, Pratt HL, et al. Characterization of platelet function in cyclic hematopoietic dogs. Exp Hematol 1991; 19(9):916-922.
12. Benson KF, Li FQ, Person RE, et al. Mutations associated with neutropenia in dogs and humans disrupt intracellular transport of neutrophil elastase. Nat Genet 2003; 35(1):90-96.
13. Callan MB, Bennett JS, Phillips DK, et al. Inherited platelet delta-storage pool disease in dogs causing severe bleeding: an animal model for a specific ADP deficiency. Thromb Haemostasis 1995; 74(3):949-953.
14. Kramer JW, Davis WC, Prieur DJ. The Chediak-Higashi syndrome of cats. Lab Invest 1977; 36(5):554-562.
15. French TW, Fox LE, Randolph JF, et al. A bleeding disorder (von Willebrand's disease) in a Himalayan cat. J Am Vet Med Assoc 1987; 190(4):437-439.
16. McCarroll DR, Waters DC, Steidley KR, et al. Canine platelet von Willebrand factor: quantification and multimeric analysis. Exp Hematol 1988; 16(11):929-937.
17. Waters DC, Eaton AH, Steidley KR, et al. Expression of von Willebrand factor in plasma and platelets of cats. Am J Vet Res 1989; 50(2):201-204.
18. Parker MT, Turrentine MA, Johnson GS. von Willebrand factor in lysates of washed canine platelets. Am J Vet Res 1991; 52(1):119-125.
19. Brooks MB, Catalfamo JL. Von Willebrand disease, In: Weiss DJ, Wardrop, KJ. eds. Schalm's Veterinary Hematology. 6th ed. Ames: Wiley-Blackwell; 2010, pp. 612-618.
20. Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. Trends Immunol 2003; 24(6):327-334.
21. Bergmeier W, Wagner DD. Inflammation, In: Michelson AD. ed. Platelets. 2nd ed. Burlington: Academic Press; 2007, pp. 713-726.
22. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38(suppl 2):S26-S34.
23. Petaja J. Inflammation and coagulation. An overview. Thromb Res 2011; 127(suppl 2):S34-S37.
24. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemostasis 2011; 105(suppl 1):S13-33.
25. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 2004; 25(9):489-495.
26. Welles EG, Boudreaux MK, Crager CS, et al. Platelet function and antithrombin, plasminogen, and fibrinolytic activities in cats with heart disease. Am J Vet Res 1994; 55(5):619-627.
27. Smith SA, Tobias AH. Feline arterial thromboembolism: an update. Vet Clin North Am Small Anim Pract 2004; 34(5):1245-1271.
28. Weiss DJ, Brazzell JL. Detection of activated platelets in dogs with primary immune-mediated hemolytic anemia. J Vet Intern Med 2006; 20(3):682-686.
29. Lunsford KV, Mackin AJ. Thromboembolic therapies in dogs and cats: an evidence-based approach. Vet Clin North Am Small Anim Pract 2007; 37(3):579-609.
30. Rauch U, Osende JI, Fuster V, et al. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 2001; 134(3):224-238.
31. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115(12):3378-3384.
32. Linden MD, Jackson DE. Platelets: pleiotropic roles in atherogenesis and atherothrombosis. Int J Biochem Cell Biol 2010; 42(11):1762-1766.
33. Ware J. Dysfunctional platelet membrane receptors: from humans to mice. Thromb Haemostasis 2004; 92(3):478-485.
34. Pretorius E, Humphries P, Ekpo OE, et al. Comparative ultrastructural analyses of mouse, rabbit, and human platelets and fibrin networks. Microsc Res Techniq 2007; 70(9):823-827.
35. Yu Y, Leng T, Yun D, et al. Global analysis of the rat and human platelet proteome - the molecular blueprint for illustrating multi-functional platelets and cross-species function evolution. Proteomics 2010; 10(13):2444-2457.
36. Cabezas M, Cabezas JA. Comparative study on the composition of platelets from the equine, bovine, ovine and porcine species. Rev Esp Fisiol 1973; 29(4):323-327.
37. Zurbano MJ, Escolar G, Heras M, et al. Characterization of adhesive and aggregating functions of pig platelets: comparative studies with human platelets and differential effects of calcium chelation. Platelets 1998; 9(5):329-337.
38. Gader AG, Ghumlas AK, Hussain MF, et al. The ultrastructure of camel blood platelets: a comparative study with human, bovine, and equine cells. Platelets 2008; 19(1):51-58.
39. Dillon AM, Heath MF. Protein tyrosine phosphorylation in equine platelets: the effect of stimulation by thrombin and platelet-activating factor (PAF). Equine Vet J 1995; 27(6):448-458.
40. Farndale RW, Napthine CS, Evans RJ, et al. The inhibition of adenylate cyclase in equine platelets by collagen and by platelet-activating factor. Platelets 1996; 7(1-2):43-46.
41. Poole AW, Heath MF, Evans RJ. ADP induces desensitisation of equine platelet aggregation responses: studies using ADP beta S, a stable analogue of ADP. Res Vet Sci 1993; 54(2):235-243.
42. Hammond A, Bailey SR, Marr CM, et al. Platelets in equine recurrent airway obstruction. Res Vet Sci 2007; 82(3):332-334.
43. Dunkel B, Rickards KJ, Page CP, et al. Platelet activation in ponies with airway inflammation. Equine Vet J 2007; 39(6):557-561.
44. Dunkel B, Rickards KJ, Werling D, et al. Neutrophil and platelet activation in equine recurrent airway obstruction is associated with increased neutrophil CD13 expression, but not platelet CD41/61 and CD62P or neutrophil-platelet aggregate formation. Vet Immunol Immunopathol 2009; 131(1-2):25-32.
45. Bailey SR, Adair HS, Reinemeyer CR, et al. Plasma concentrations of endotoxin and platelet activation in the developmental stage of oligofructose-induced laminitis. Vet Immunol Immunopathol 2009; 129(3-4):167-173.
46. Bailey SR, Andrews MJ, Elliott J, et al. Actions and interactions of ADP, 5- HT, histamine and PAF on equine platelets. Res Vet Sci 2000; 68(2):175-180.
47. Weiss DJ, Evanson OA, McClenahan D, et al. Effect of a competitive inhibitor of platelet aggregation on experimentally induced laminitis in ponies. Am J Vet Res 1998; 59(7):814-817.
48. Nylander S, Mattsson C, Lindahl TL. Characterisation of species differences in the platelet ADP and thrombin response. Thromb Res 2006; 117(5):543-549.
49. Mezzano D, Aranda E, Foradori A. Comparative study of size, total protein, fibrinogen and 5-HT content of human and canine platelet density subpopulations. Thromb Haemostasis 1986; 56(3):288-292.
50. Nurden AT, Butcher PD, Hawkey CM. Comparative studies on the glycoprotein composition of mammalian platelets. Comp Biochem Phys B 1977; 56(4):407-413.
51. Leach CM, Thorburn GD. A comparative study of collagen induced thromboxane release from platelets of different species: implications for human atherosclerosis models. Prostaglandins 1982; 24(1):47-59.
52. Callan MB, Shofer FS, Wojenski C, et al. Chrono-lume and magnesium potentiate aggregation of canine but not human platelets in citrated platelet-rich plasma. Thromb Haemostasis 1998; 80(1):176-180.
53. Soloviev MV, Okazaki Y, Harasaki H. Whole blood platelet aggregation in humans and animals: a comparative study. J Surg Res 1999; 82(2):180-187.
54. Bright JM, Dowers K, Hellyer P. In vitro anti-aggregatory effects of the GP IIb/IIIa antagonist eptifibatide on feline platelets. J Vet Intern Med 2002; 16(6):v.
55. Lipscomb DL, Bourne C, Boudreaux MK. Nucleotide sequence of the canine alphaIIb gene from platelet-derived cDNA. Am J Vet Res 2001; 62(9):1486-1492.
56. Fang J, Jensen ES, Boudreaux MK, et al. Platelet gene therapy improves hemostatic function for integrin {alpha}IIb{beta}3-deficient dogs. Proc Natl Acad Sci USA 2011; 108(23):9583-9588.
57. Nielsen LA, Zois NE, Pedersen HD, et al. Platelet function in dogs: breed differences and effect of acetylsalicylic acid administration. Vet Clin Pathol 2007; 36(3):267-273.
58. Brass LF. Thrombin and platelet activation. Chest 2003; 124(suppl 3):18S-25S.
59. Rivera J, Lozano ML, Navarro-Nunez L, et al. Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica 2009; 94(5):700-711.
60. Nachman RL, Rafii S. Platelets, petechiae, and preservation of the vascular wall. N Engl J Med 2008; 359(12):1261-1270.
61. Behnke O. The morphology of blood platelet membrane systems. Semin Hematol 1970; 3(4):3-16.
62. Choi W, Karim ZA, Whiteheart SW. Protein expression in platelets from six species that differ in their open canalicular system. Platelets 2010; 21(3):167-175.
63. White JG. The secretory pathway of bovine platelets. Blood 1987; 69(3):878-885.
64. Escolar G, Leistikow E, White JG. The fate of the open canalicular system in surface and suspension-activated platelets. Blood 1989; 74(6):1983-1988.
65. Heemskerk JW, Bevers EM, Lindhout T. Platelet activation and blood coagulation. Thromb Haemostasis 2002; 88(2):186-193.
66. Kalafatis M, Swords NA, Rand MD, et al. Membrane-dependent reactions in blood coagulation: role of the vitamin K-dependent enzyme complexes. Biochim Biophys Acta 1994; 1227(3):113-129.
67. Lawson JH, Kalafatis M, Stram S, et al. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269(37):23357-23366.
68. Rosing J, van Rijn JL, Bevers EM, et al. The role of activated human platelets in prothrombin and factor X activation. Blood 1985; 65(2):319-332.
69. Patterson WR, Cissik JH. A comparison of human and canine platelet fatty acid composition. Comp Biochem Phys B 1991; 99(1):147-150.
70. Schroit AJ, Zwaal RF. Transbilayer movement of phospholipids in red cell and platelet membranes. Biochim Biophys Acta 1991; 1071(3):313-329.
71. Daleke DL. Regulation of transbilayer plasma membrane phospholipid asymmetry. J Lipid Res 2003; 44(2):233-242.
72. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89(4):1121-1132.
73. Wolfs JL, Comfurius P, Rasmussen JT, et al. Activated scramblase and inhibited aminophospholipid translocase cause phosphatidylserine exposure in a distinct platelet fraction. Cell Mol Life Sci 2005; 62(13):1514-1525.
74. Comfurius P, Senden JM, Tilly RH, et al. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochim Biophys Acta 1990; 1026(2):153-160.
75. Bevers EM, Tilly RH, Senden JM, et al. Exposure of endogenous phosphatidylserine at the outer surface of stimulated platelets is reversed by restoration of aminophospholipid translocase activity. Biochemistry 1989; 28(6):2382-2387.
76. Bevers EM, Comfurius P, Zwaal RF. Mechanisms involved in platelet procoagulant response. Adv Exp Med Biol 1993; 344:195-207.
77. Weiss HJ, Vicic WJ, Lages BA, et al. Isolated deficiency of platelet procoagulant activity. Am J Med 1979; 67(2):206-213.
78. Sims PJ, Wiedmer T, Esmon CT, et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264(29):17049-17057.
79. Toti F, Satta N, Fressinaud E, et al. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 1996; 87(4):1409-1415.
80. Brooks MB, Catalfamo JL, Brown HA, et al. A hereditary bleeding disorder of dogs caused by a lack of platelet procoagulant activity. Blood 2002; 99(7):2434-2441.
81. Brooks M, Etter K, Catalfamo J, et al. A genome-wide linkage scan in German shepherd dogs localizes canine platelet procoagulant deficiency (Scott syndrome) to canine chromosome 27. Gene 2010; 450(1-2):70-75.
82. Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 2000; 275(23):17221-17224.
83. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387(6633):569-572.
84. Dorahy DJ, Lincz LF, Meldrum CJ, et al. Biochemical isolation of a membrane microdomain from resting platelets highly enriched in the plasma membrane glycoprotein CD36. Biochem J 1996; 319(Pt 1):67-72.
85. Lopez JA, del Conde I, Shrimpton CN. Receptors, rafts, and microvesicles in thrombosis and inflammation. J Thromb Haemostasis 2005; 3(8):1737-1744.
86. Gousset K, Wolkers WF, Tsvetkova NM, et al. Evidence for a physiological role for membrane rafts in human platelets. J Cell Physiol 2002; 190(1):117-128.
87. Bodin S, Tronchere H, Payrastre B. Lipid rafts are critical membrane domains in blood platelet activation processes. Biochim Biophys Acta 2003; 1610(2):247-257.
88. White JG. Platelet structure, In: Michelson AD. ed. Platelets, 2nd ed. Burlington: Academic Press; 2007, pp. 45-73.
89. Schwer HD, Lecine P, Tiwari S, et al. A lineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood platelets. Curr Biol 2001; 11(8):579-586.
90. Italiano JE, Jr., Bergmeier W, Tiwari S, et al. Mechanisms and implications of platelet discoid shape. Blood 2003; 101(12):4789-4796.
91. Davis B, Toivio-Kinnucan M, Schuller S, et al. Mutation in beta1-tubulin correlates with macrothrombocytopenia in Cavalier King Charles Spaniels. J Vet Intern Med 2008; 22(3):540-545.
92. Boudreaux MK, Osborne CD, Herre AC, et al. Unique structure of the M loop region of beta1-tubulin may contribute to size variability of platelets in the family felidae. Vet Clin Pathol 2010; 39(4):417-423.
93. Patel-Hett S, Richardson JL, Schulze H, et al. Visualization of microtubule growth in living platelets reveals a dynamic marginal band with multiple microtubules. Blood 2008; 111(9):4605-4616.
94. Hartwig JH. The platelet cytoskeleton, In: Michelson AD. ed. Platelets, 2nd ed. Burlington: Academic Press; 2007, pp. 75-98.
95. Nachmias VT, Cassimeris L, Golla R, et al. Thymosin beta 4 (T beta 4) in activated platelets. Eur J Cell Biol 1993; 61(2):314-320.
96. Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 2009; 23(4):177-189.
97. King SM, Reed GL. Development of platelet secretory granules. Semin Cell Dev Biol 2002; 13(4):293-302.
98. Rendu F, Brohard-Bohn B. The platelet release reaction: granules' constituents, secretion and functions. Platelets 2001; 12(5):261-273.
99. Harrison P, Wilbourn B, Debili N, et al. Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. J Clin Invest 1989; 84(4):1320-1324.
100. Heilmann E, Hynes LA, Friese P, et al. Dog platelets accumulate intracellular fibrinogen as they age. J Cell Physiol 1994; 161(1):23-30.
101. Camire RM, Pollak ES, Kaushansky K, et al. Secretable human platelet-derived factor V originates from the plasma pool. Blood 1998; 92(9):3035-3041.
102. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75(7):1383-1395.
103. Lopez JA, Andrews RK, Afshar-Kharghan V, et al. Bernard-Soulier syndrome. Blood 1998; 91(12):4397-4418.
104. Phillips DR, Jenkins CS, Luscher EF, et al. Molecular differences of exposed surface proteins on thrombasthenic platelet plasma membranes. Nature 1975; 257(5527):599-600.
105. Nurden AT, Caen JP. Specific roles for platelet surface glycoproteins in platelet function. Nature 1975; 255(5511):720-722.
106. White JG. Functional significance of mobile receptors on human platelets. Arterioscler Thromb 1993; 13(8):1236-1243.
107. Yeaman MR, Bayer, AS. Antimicrobial host defense, In: Michelson AD. ed. Platelets, 2nd ed. Burlington: Academic Press; 2007, pp. 727-756.
108. Brill A, Varon, D. Angiogenesis, In: Michelson AD. ed. Platelets, 2nd ed. Burlington: Academic Press; 2007, pp. 757-768.
109. Clemetson KJ, Clemetson JM. Platelet receptors, In: Michelson AD. ed. Platelets, 2nd ed. Burlington: Academic Press; 2007, pp. 117-143.
110. Watson SP, Auger JM, McCarty OJ, et al. GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemostasis 2005; 3(8):1752-1762.
111. Bennett JS, Berger BW, Billings PC. The structure and function of platelet integrins. J Thromb Haemostasis 2009; 7(suppl 1):200-205.
112. Li Z, Delaney MK, O'Brien KA, et al. Signaling during platelet adhesion and activation. Arterioscl Throm Vasc Biol 2010; 30(12):2341-2349.
113. Andrews RK, Gardiner EE, Shen Y, et al. Glycoprotein Ib-IX-V. Int J Biochem Cell B 2003; 35(8):1170-1174.
114. Coller BS, Shattil SJ. The GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2008; 112(8):3011-3025.
115. Kasirer-Friede A, Kahn ML, Shattil SJ. Platelet integrins and immunoreceptors. Immunol Rev 2007; 218:247-264.
116. Gruner S, Prostredna M, Schulte V, et al. Multiple integrin-ligand interactions synergize in shear-resistant platelet adhesion at sites of arterial injury in vivo. Blood 2003; 102(12):4021-4027.
117. Wencel-Drake JD, Plow EF, Kunicki TJ, et al. Localization of internal pools of membrane glycoproteins involved in platelet adhesive responses. Am J Pathol 1986; 124(2):324-334.
118. Niiya K, Hodson E, Bader R, et al. Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation. Blood 1987; 70(2):475-483.
119. Carrell NA, Fitzgerald LA, Steiner B, et al. Structure of human platelet membrane glycoproteins IIb and IIIa as determined by electron microscopy. J Biol Chem 1985; 260(3):1743-1749.
120. Takagi J, Petre BM, Walz T, et al. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell 2002; 110(5):599-511.
121. Adair BD, Yeager M. Three-dimensional model of the human platelet integrin alpha IIbbeta 3 based on electron cryomicroscopy and x-ray crystallography. Proc Natl Acad Sci USA 2002; 99(22):14059-14064.
122. Hughes PE, Diaz-Gonzalez F, Leong L, et al. Breaking the integrin hinge. A defined structural constraint regulates integrin signaling. J Biol Chem 1996; 271(12):6571-6574.
123. Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol 2010; 11(4):288-300.
124. Luo BH, Carman CV, Takagi J, et al. Disrupting integrin transmembrane domain heterodimerization increases ligand binding affinity, not valency or clustering. Proc Natl Acad Sci USA 2005; 102(10):3679-3684.
125. Li R, Mitra N, Gratkowski H, et al. Activation of integrin alphaIIbbeta3 by modulation of transmembrane helix associations. Science 2003; 300(5620):795-798.
126. Vinogradova O, Velyvis A, Velyviene A, et al. A structural mechanism of integrin alpha(IIb)beta(3) "inside-out" activation as regulated by its cytoplasmic face. Cell 2002; 110(5):587-597.
127. Adair BD, Xiong JP, Maddock C, et al. Three-dimensional EM structure of the ectodomain of integrin {alpha}V{beta}3 in a complex with fibronectin. J Cell Biol 2005; 168(7):1109-1118.
128. Xiong JP, Stehle T, Goodman SL, et al. New insights into the structural basis of integrin activation. Blood 2003; 102(4):1155-1159.
129. Plow EF, Haas TA, Zhang L, et al. Ligand binding to integrins. J Biol Chem 2000; 275(29):21785-21788.
130. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003; 102(2):449-461.
131. Deckmyn H, Chew SL, Vermylen J. Lack of platelet response to collagen associated with an autoantibody against glycoprotein Ia: a novel cause of acquired qualitative platelet dysfunction. Thromb Haemostasis 1990; 64(1):74-79.
132. Handa M, Watanabe K, Kawai Y, et al. Platelet unresponsiveness to collagen: involvement of glycoprotein Ia-IIa (alpha 2 beta 1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Haemostasis 1995; 73(3):521-528.
133. Holtkotter O, Nieswandt B, Smyth N, et al. Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J Biol Chem 2002; 277(13):10789-10794.
134. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94(5):657-666.
135. Siljander P, Lassila R. Studies of adhesion-dependent platelet activation: distinct roles for different participating receptors can be dissociated by proteolysis of collagen. Arterioscler Thromb Vasc Biol 1999; 19(12):3033-3043.
136. Suzuki-Inoue K, Yatomi Y, Asazuma N, et al. Rac, a small guanosine triphosphate-binding protein, and p21-activated kinase are activated during platelet spreading on collagen-coated surfaces: roles of integrin alpha(2)beta(1). Blood 2001; 98(13):3708-3716.
137. Inoue O, Suzuki-Inoue K, Dean WL, et al. Integrin alpha2beta1mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2. J Cell Biol 2003; 160(5):769-780.
138. Kuijpers MJ, Schulte V, Bergmeier W, et al. Complementary roles of glycoprotein VI and alpha2beta1 integrin in collagen-induced thrombus formation in flowing whole blood ex vivo. FASEB J 2003; 17(6):685-687.
139. Van de Walle GR, Vanhoorelbeke K, Majer Z, et al. Two functional active conformations of the integrin {alpha}2{beta}1, depending on activation condition and cell type. J Biol Chem 2005; 280(44):36873-36882.
140. Moroi M, Jung SM, Nomura S, et al. Analysis of the involvement of the von Willebrand factor-glycoprotein Ib interaction in platelet adhesion to a collagen-coated surface under flow conditions. Blood 1997; 90(11):4413-4424.
141. Arya M, Anvari B, Romo GM, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 2002; 99(11):3971-3977.
142. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100(12):4033-4039.
143. Lammle B, Kremer Hovinga JA, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemostasis 2005; 3(8):1663-1675.
144. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 1996; 84(2):289-297.
145. Ramakrishnan V, DeGuzman F, Bao M, et al. A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. Proc Natl Acad Sci USA 2001; 98(4):1823-1828.
146. Jurk K, Clemetson KJ, de Groot PG, et al. Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor. FASEB J 2003; 17(11):1490-1492.
147. Romo GM, Dong JF, Schade AJ, et al. The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med 1999; 190(6):803-814.
148. Simon DI, Chen Z, Xu H, et al. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18). J Exp Med 2000; 192(2):193-204.
149. Baglia FA, Badellino KO, Li CQ, et al. Factor XI binding to the platelet glycoprotein Ib-IX-V complex promotes factor XI activation by thrombin. J Biol Chem 2002; 277(3):1662-1668.
150. Fox JE. The platelet cytoskeleton. Thromb Haemostasis 1993; 70(6):884-893.
151. Andrews RK, Munday AD, Mitchell CA, et al. Interaction of calmodulin with the cytoplasmic domain of the platelet membrane glycoprotein Ib-IX-V complex. Blood 2001; 98(3):681-687.
152. Mangin P, David T, Lavaud V, et al. Identification of a novel 14-3-3zeta binding site within the cytoplasmic tail of platelet glycoprotein Ibalpha. Blood 2004; 104(2):420-427.
153. Dai K, Bodnar R, Berndt MC, et al. A critical role for 14-3-3zeta protein in regulating the VWF binding function of platelet glycoprotein Ib-IX and its therapeutic implications. Blood 2005; 106(6):1975-1981.
154. Munday AD, Berndt MC, Mitchell CA. Phosphoinositide 3-kinase forms a complex with platelet membrane glycoprotein Ib-IX-V complex and 14-3-3zeta. Blood 2000; 96(2):577-584.
155. Jackson SP, Yap CL, Anderson KE. Phosphoinositide 3-kinases and the regulation of platelet function. Biochem Soc Trans 2004; 32(Pt 2):387-392.
156. Falati S, Edmead CE, Poole AW. Glycoprotein Ib-V-IX, a receptor for von Willebrand factor, couples physically and functionally to the Fc receptor gamma-chain, Fyn, and Lyn to activate human platelets. Blood 1999; 94(5):1648-1656.
157. Wu Y, Suzuki-Inoue K, Satoh K, et al. Role of Fc receptor gamma-chain in platelet glycoprotein Ib-mediated signaling. Blood 2001; 97(12):3836-3845.
158. Morton LF, Hargreaves PG, Farndale RW, et al. Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity. Biochem J 1995; 306(Pt 2):337-344.
159. Gibbins JM, Okuma M, Farndale R, et al. Glycoprotein VI is the collagen receptor in platelets which underlies tyrosine phosphorylation of the Fc receptor gamma-chain. FEBS Lett 1997; 413(2):255-259.
160. Tsuji M, Ezumi Y, Arai M, et al. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem 1997; 272(38):23528-23531.
161. Gibbins J, Asselin J, Farndale R, et al. Tyrosine phosphorylation of the Fc receptor gamma-chain in collagen-stimulated platelets. J Biol Chem 1996; 271(30):18095-18099.
162. Suzuki-Inoue K, Tulasne D, Shen Y, et al. Association of Fyn and Lyn with the proline-rich domain of glycoprotein VI regulates intracellular signaling. J Biol Chem 2002; 277(24):21561-21566.
163. Poole A, Gibbins JM, Turner M, et al. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997; 16(9):2333-2341.
164. Inoue O, Suzuki-Inoue K, McCarty OJ, et al. Laminin stimulates spreading of platelets through integrin alpha6beta1-dependent activation of GPVI. Blood 2006; 107(4):1405-1412.
165. Sonnenberg A, Modderman PW, Hogervorst F. Laminin receptor on platelets is the integrin VLA-6. Nature 1988; 336(6198):487-489.
166. Marks F, Klingmueller U, Mueller-Decker K. Signal transduction by receptors with seven transmembrane domains, In: Cellular Signal Processing, 1st ed. New York: Garland Science; 2009, pp. 183-218.
167. Vu TK, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64(6):1057-1068.
168. Chen J, Ishii M, Wang L, et al. Thrombin receptor activation. Confirmation of the intramolecular tethered liganding hypothesis and discovery of an alternative intermolecular liganding mode. J Biol Chem 1994; 269(23):16041-16045.
169. Ishihara H, Connolly AJ, Zeng D, et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997; 386(6624):502-506.
170. Xu WF, Andersen H, Whitmore TE, et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci USA 1998; 95(12):6642-6646.
171. Nystedt S, Emilsson K, Wahlestedt C, et al. Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 1994; 91(20):9208-9212.
172. Molino M, Barnathan ES, Numerof R, et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 1997; 272(7):4043-4049.
173. Covic L, Gresser AL, Kuliopulos A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 2000; 39(18):5458-5467.
174. Kahn ML, Zheng YW, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394(6694):690-694.
175. Nakanishi-Matsui M, Zheng YW, Sulciner DJ, et al. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 2000; 404(6778):609-613.
176. Boudreaux MK. Platelet Structure, In: Weiss DJ, Wardrop KJ. eds. Schalm's Veterinary Hematology, 6th ed. Ames: Academic Press; 2010, pp. 561-568.
177. Connolly TM, Condra C, Feng DM, et al. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemostasis 1994; 72(4):627-633.
178. Derian CK, Santulli RJ, Tomko KA, et al. Species differences in platelet responses to thrombin and SFLLRN. receptor-mediated calcium mobilization and aggregation, and regulation by protein kinases. Thromb Res 1995; 78(6):505-519.
179. Brass LF, Vassallo RR, Jr., Belmonte E, et al. Structure and function of the human platelet thrombin receptor. Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus. J Biol Chem 1992; 267(20):13795-13798.
180. Molino M, Bainton DF, Hoxie JA, et al. Thrombin receptors on human platelets. Initial localization and subsequent redistribution during platelet activation. J Biol Chem 1997; 272(9):6011-6017.
181. Brass LF, Manning DR, Cichowski K, et al. Signaling through G proteins in platelets: to the integrins and beyond. Thromb Haemostasis 1997; 78(1):581-589.
182. Hart MJ, Jiang X, Kozasa T, et al. Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by Galpha13. Science 1998; 280(5372):2112-2114.
183. Kozasa T, Jiang X, Hart MJ, et al. p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science 1998; 280(5372):2109-2111.
184. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19(10):2281-2285.
185. Packham MA, Mustard JF. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective. Semin Thromb Hemost 2005; 31(2):129-138.
186. Li Z, Zhang G, Le Breton GC, et al. Two waves of platelet secretion induced by thromboxane A2 receptor and a critical role for phosphoinositide 3-kinases. J Biol Chem 2003; 278(33):30725-30731.
187. Oury C, Toth-Zsamboki E, Thys C, et al. The ATP-gated P2́1 ion channel acts as a positive regulator of platelet responses to collagen. Thromb Haemostasis 2001; 86(5):1264-1271.
188. Marcus AJ, Broekman MJ, Drosopoulos JH, et al. Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotection. Semin Thromb Hemost 2005; 31(2):234-246.
189. Ohlmann P, Laugwitz KL, Nurnberg B, et al. The human platelet ADP receptor activates Gi2 proteins. Biochem J 1995; 312(Pt 3):775-779.
190. Jantzen HM, Milstone DS, Gousset L, et al. Impaired activation of murine platelets lacking G alpha(i2). J Clin Invest 2001; 108(3):477-483.
191. Geiger J, Teichmann L, Grossmann R, et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005; 51(6):957-965.
192. Daniel JL, Dangelmaier C, Jin J, et al. Role of intracellular signaling events in ADP-induced platelet aggregation. Thromb Haemostasis 1999; 82(4):1322-1326.
193. Milburn CC, Deak M, Kelly SM, et al. Binding of phosphatidylinositol 3, 4, 5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem J 2003; 375(Pt 3):531-538.
194. Kim S, Jin J, Kunapuli SP. Akt activation in platelets depends on Gi signaling pathways. J Biol Chem 2004; 279(6):4186-4195.
195. Laffargue M, Ragab-Thomas JM, Ragab A, et al. Phosphoinositide 3-kinase and integrin signaling are involved in activation of Bruton tyrosine kinase in thrombin-stimulated platelets. FEBS Lett 1999; 443(1):66-70.
196. Jackson SP, Schoenwaelder SM, Goncalves I, et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med 2005; 11(5):507-514.
197. Garcia A, Kim S, Bhavaraju K, et al. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signaling pathways. Biochem J 2010; 429(2):369-377.
198. Hirsch E, Bosco O, Tropel P, et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J 2001; 15(11):2019-2021.
199. Woulfe DS. Akt signaling in platelets and thrombosis. Expert Rev Hematol 2010; 3(1):81-91.
200. Mills DC. ADP receptors on platelets. Thromb Haemostasis 1996; 76(6):835-856.
201. Baurand A, Raboisson P, Freund M, et al. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol 2001; 412(3):213-221.
202. Hechler B, Eckly A, Ohlmann P, et al. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 1998; 103(3):858-866.
203. Sage SO, Reast R, Rink TJ. ADP evokes biphasic Ca2+ influx in fura-2-loaded human platelets. Evidence for Ca2+ entry regulated by the intracellular Ca2 +store. Biochem J 1990; 265(3):675-680.
204. Hardy AR, Jones ML, Mundell SJ, et al. Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets. Blood 2004; 104(6):1745-1752.
205. Soulet C, Hechler B, Gratacap MP, et al. A differential role of the platelet ADP receptors P2Y1 and P2Y12 in Rac activation. J Thromb Haemostasis 2005; 3(10):2296-2306.
206. Paul BZ, Daniel JL, Kunapuli SP. Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change. J Biol Chem 1999; 274(40):28293-28300.
207. Baurand A, Eckly A, Bari N, et al. Desensitization of the platelet aggregation response to ADP: differential down-regulation of the P2Y1 and P2cyc receptors. Thromb Haemostasis 2000; 84(3):484-491.
208. Baurand A, Eckly A, Hechler B, et al. Differential regulation and relocalization of the platelet P2Y receptors after activation: a way to avoid loss of hemostatic properties? Mol Pharmacol 2005; 67(3):721-733.
209. Hardy AR, Conley PB, Luo J, et al. P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood 2005; 105(9):3552-3560.
210. Mundell SJ, Barton JF, Mayo-Martin MB, et al. Rapid resensitization of purinergic receptor function in human platelets. J Thromb Haemostasis 2008; 6(8):1393-1404.
211. Cosemans JM, Munnix IC, Wetzker R, et al. Continuous signaling via PI3 K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 2006; 108(9):3045-3052.
212. Goto S, Tamura N, Ishida H, et al. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling. J Am Coll Cardiol 2006; 47(1):155-162.
213. Canobbio I, Reineri S, Sinigaglia F, et al. A role for p38 MAP kinase in platelet activation by von Willebrand factor. Thromb Haemostasis 2004; 91(1):102-110.
214. Djellas Y, Manganello JM, Antonakis K, et al. Identification of Galpha13 as one of the G-proteins that couple to human platelet thromboxane A2 receptors. J Biol Chem 1999; 274(20):14325-14330.
215. Klages B, Brandt U, Simon MI, et al. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999; 144(4):745-754.
216. Johnson GJ, Leis LA, Rao GH, et al. Arachidonate-induced platelet aggregation in the dog. Thromb Res 1979; 14(1):147-154.
217. Johnson GJ, Rao GH, Leis LA, et al. Effect of agents that alter cyclic AMP on arachidonate-induced platelet aggregation in the dog. Blood 1980; 55(5):722-729.
218. Johnson GJ, Leis LA, King RA. Thromboxane responsiveness of dog platelets is inherited as an autosomal recessive trait. Thromb Haemostasis 1991; 65(5):578-580.
219. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002; 296(5567):539-541.
220. Wise H, Wong YH, Jones RL. Prostanoid signal integration and cross talk. Neurosignals 2002; 11(1):20-28.
221. Tateson JE, Moncada S, Vane JR. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1977; 13(3):389-397.
222. Gorman RR, Bunting S, Miller OV. Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 1977; 13(3):377-388.
223. Siess W. Molecular mechanisms of platelet activation. Physiol Rev 1989; 69(1):58-178.
224. Hathaway DR, Eaton CR, Adelstein RS. Regulation of human platelet myosin light chain kinase by the catalytic subunit of cyclic AMP-dependent protein kinase. Nature 1981; 291(5812):252-256.
225. Siess W, Lapetina EG. Prostacyclin inhibits platelet aggregation induced by phorbol ester or Ca2 +ionophore at steps distal to activation of protein kinase C and Ca2+-dependent protein kinases. Biochem J 1989; 258(1):57-65.
226. Braun A, Varga-Szabo D, Kleinschnitz C, et al. Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation. Blood 2009; 113(9):2056-2063.
227. Gilio K, van Kruchten R, Braun A, et al. Roles of platelet STIM1 and Orai1 in glycoprotein VI- and thrombin-dependent procoagulant activity and thrombus formation. J Biol Chem 2010; 285(31):23629-23638.
228. Crittenden JR, Bergmeier W, Zhang Y, et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med 2004; 10(9):982-986.
229. Stefanini L, Bergmeier W. CalDAG-GEFI and platelet activation. Platelets 2010; 21(4):239-243.
230. Stefanini L, Roden RC, Bergmeier W. CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. Blood 2009; 114(12):2506-2514.
231. Cifuni SM, Wagner DD, Bergmeier W. CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin alphaIIbbeta3 in platelets. Blood 2008; 112(5):1696-1703.
232. Bergmeier W, Goerge T, Wang HW, et al. Mice lacking the signaling molecule CalDAG-GEFI represent a model for leukocyte adhesion deficiency type III. J Clin Invest 2007; 117(6):1699-1707.
233. Chrzanowska-Wodnicka M, Smyth SS, Schoenwaelder SM, et al. Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest 2005; 115(3):680-687.
234. Lafuente EM, van Puijenbroek AA, Krause M, et al. RIAM, an Ena/VASP and Profilin ligand, interacts with Rap1-GTP and mediates Rap1-induced adhesion. Dev Cell 2004; 7(4):585-595.
235. Han J, Lim CJ, Watanabe N, et al. Reconstructing and deconstructing agonist-induced activation of integrin alphaIIbbeta3. Curr Biol 2006; 16(18):1796-1806.
236. Banno A, Ginsberg MH. Integrin activation. Biochem Soc T 2008; 36(Pt 2):229-234.
237. Shattil SJ. The beta3 integrin cytoplasmic tail: protein scaffold and control freak. J Thromb Haemostasis 2009; 7(suppl 1):210-213.
238. Tadokoro S, Shattil SJ, Eto K, et al. Talin binding to integrin beta tails: a final common step in integrin activation. Science 2003; 302(5642):103-106.
239. Moser M, Legate KR, Zent R, et al. The tail of integrins, talin, and kindlins. Science 2009; 324(5929):895-899.
240. Calderwood DA, Ginsberg MH. Talin forges the links between integrins and actin. Nat Cell Biol 2003; 5(8):694-697.
241. Anthis NJ, Wegener KL, Ye F, et al. The structure of an integrin/talin complex reveals the basis of inside-out signal transduction. EMBO J 2009; 28(22):3623-3632.
242. Goult BT, Bate N, Anthis NJ, et al. The structure of an interdomain complex that regulates talin activity. J Biol Chem 2009; 284(22):15097-15106.
243. Goksoy E, Ma YQ, Wang X, et al. Structural basis for the autoinhibition of talin in regulating integrin activation. Mol Cell 2008; 31(1):124-133.
244. Rees DJ, Ades SE, Singer SJ, et al. Sequence and domain structure of talin. Nature 1990; 347(6294):685-689.
245. Calderwood DA, Zent R, Grant R, et al. The Talin head domain binds to integrin beta subunit cytoplasmic tails and regulates integrin activation. J Biol Chem 1999; 274(40):28071-28074.
246. Petrich BG. Talin-dependent integrin signalling in vivo. Thromb Haemostasis 2009; 101(6):1020-1024.
247. Nieswandt B, Moser M, Pleines I, et al. Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. J Exp Med 2007; 204(13):3113-3118.
248. Petrich BG, Marchese P, Ruggeri ZM, et al. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med 2007; 204(13):3103-3111.
249. Calderwood DA, Yan B, de Pereda JM, et al. The phosphotyrosine binding-like domain of talin activates integrins. J Biol Chem 2002; 277(24):21749-21758.
250. Garcia-Alvarez B, de Pereda JM, Calderwood DA, et al. Structural determinants of integrin recognition by talin. Mol Cell 2003; 11(1):49-58.
251. Vinogradova O, Haas T, Plow EF, et al. A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit. Proc Natl Acad Sci USA 2000; 97(4):1450-1455.
252. Wegener KL, Partridge AW, Han J, et al. Structural basis of integrin activation by talin. Cell 2007; 128(1):171-182.
253. Ulmer TS, Calderwood DA, Ginsberg MH, et al. Domain-specific interactions of talin with the membrane-proximal region of the integrin beta3 subunit. Biochemistry 2003; 42(27):8307-8312.
254. Kim C, Lau TL, Ulmer TS, et al. Interactions of platelet integrin alphaIIb and beta3 transmembrane domains in mammalian cell membranes and their role in integrin activation. Blood 2009; 113(19):4747-4753.
255. Nieswandt B, Varga-Szabo D, Elvers M. Integrins in platelet activation. J Thromb Haemostasis 2009; 7(suppl 1):206-209.
256. Ma YQ, Qin J, Wu C, et al. Kindlin-2 (Mig-2): a co-activator of beta3 integrins. J Cell Biol 2008; 181(3):439-446.
257. Moser M, Nieswandt B, Ussar S, et al. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 2008; 14(3):325-330.
258. Svensson L, Howarth K, McDowall A, et al. Leukocyte adhesion deficiency-III is caused by mutations in KINDLIN3 affecting integrin activation. Nat Med 2009; 15(3):306-312.
259. Boudreaux MK, Wardrop KJ, Kiklevich V, et al. A mutation in the canine Kindlin-3 gene associated with increased bleeding risk and susceptibility to infections. Thromb Haemostasis 2010; 103(2):475-477.
260. Etzioni A, Alon R. Leukocyte adhesion deficiency III: a group of integrin activation defects in hematopoietic lineage cells. Curr Opin Allergy Clin Immunol 2004; 4(6):485-490.
261. Kilic SS, Etzioni A. The clinical spectrum of leukocyte adhesion deficiency (LAD) III due to defective CalDAG-GEF1. J Clin Immunol 2009; 29(1):117-122.
262. Moser M, Nieswandt B, Ussar S, et al. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 2008; 14(3):325-330.
263. Kloeker S, Major MB, Calderwood DA, et al. The Kindler syndrome protein is regulated by transforming growth factor-beta and involved in integrin-mediated adhesion. J Biol Chem 2004; 279(8):6824-6833.
264. Alberio L, Dale GL. Review article: platelet-collagen interactions: membrane receptors and intracellular signalling pathways. Eur J Clin Invest 1999; 29(12):1066-1076.
265. Jung SM, Moroi M. Activation of the platelet collagen receptor integrin alpha(2)beta(1): its mechanism and participation in the physiological functions of platelets. Trends Cardiovasc Med 2000; 10(7):285-292.
266. Savage B, Ginsberg MH, Ruggeri ZM. Influence of fibrillar collagen structure on the mechanisms of platelet thrombus formation under flow. Blood 1999; 94(8):2704-2715.
267. Kato K, Kanaji T, Russell S, et al. The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood 2003; 102(5):1701-1707.
268. Nieswandt B, Brakebusch C, Bergmeier W, et al. Glycoprotein VI but not alpha2beta1 integrin is essential for platelet interaction with collagen. EMBO J 2001; 20(9):2120-2130.
269. Lecut C, Schoolmeester A, Kuijpers MJ, et al. Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation. Arterioscler Thromb Vasc Biol 2004; 24(9):1727-1733.
270. Pula G, Poole AW. Critical roles for the actin cytoskeleton and cdc42 in regulating platelet integrin alpha2beta1. Platelets 2008; 19(3):199-210.
271. Obergfell A, Eto K, Mocsai A, et al. Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton. J Cell Biol 2002; 157(2):265-275.
272. Dorahy DJ, Berndt MC, Burns GF. Capture by chemical crosslinkers provides evidence that integrin alpha IIb beta 3 forms a complex with protein tyrosine kinases in intact platelets. Biochem J 1995; 309(Pt 2):481-490.
273. Arias-Salgado EG, Haj F, Dubois C, et al. PTP-1B is an essential positive regulator of platelet integrin signaling. J Cell Biol 2005; 170(5):837-845.
274. Vijayan KV, Liu Y, Li TT, et al. Protein phosphatase 1 associates with the integrin alphaIIb subunit and regulates signaling. J Biol Chem 2004; 279(32):33039-33042.
275. Kasirer-Friede A, Ruggeri ZM, Shattil SJ. Role for ADAP in shear flow-induced platelet mechanotransduction. Blood 2010; 115(11):2274-2282.
276. Banfic H, Tang X, Batty IH, et al. A novel integrin-activated pathway forms PKB/Akt-stimulatory phosphatidylinositol 3, 4-bisphosphate via phosphatidylinositol 3-phosphate in platelets. J Biol Chem 1998; 273(1):13-16.
277. Goncalves I, Hughan SC, Schoenwaelder SM, et al. Integrin alpha IIb beta 3-dependent calcium signals regulate platelet-fibrinogen interactions under flow. Involvement of phospholipase C gamma 2. J Biol Chem 2003; 278(37):34812-34822.
278. Wonerow P, Pearce AC, Vaux DJ, et al. A critical role for phospholipase C gamma2 in alphaIIbbeta3-mediated platelet spreading. J Biol Chem 2003; 278(39):37520-37529.
279. Jones ML, Craik JD, Gibbins JM, et al. Regulation of SHP-1 tyrosine phosphatase in human platelets by serine phosphorylation at its C terminus. J Biol Chem 2004; 279(39):40475-40483.
280. Gao J, Zoller KE, Ginsberg MH, et al. Regulation of the pp72syk protein tyrosine kinase by platelet integrin alpha IIb beta 3. EMBO J 1997; 16(21):6414-6425.
281. Miranti CK, Leng L, Maschberger P, et al. Identification of a novel integrin signaling pathway involving the kinase Syk and the guanine nucleotide exchange factor Vav1. Curr Biol 1998; 8(24):1289-1299.
282. Saci A, Rendu F, Bachelot-Loza C. Platelet alpha IIb-beta 3 integrin engagement induces the tyrosine phosphorylation of Cbl and its association with phosphoinositide 3-kinase and Syk. Biochem J 2000; 351(Pt 3):669-676.
283. Judd BA, Koretzky GA. The role of the adapter molecule SLP-76 in platelet function. Oncogene 2001; 20(44):6291-6299.
284. Fang N, Motto DG, Ross SE, et al. Tyrosines 113, 128, and 145 of SLP-76 are required for optimal augmentation of NFAT promoter activity.J Immunol 1996; 157(9):3769-3773.
285. Bagrodia S, Cerione RA. Pak to the future. Trends Cell Biol 1999; 9(9):350-355.
286. McCarty OJ, Larson MK, Auger JM, et al. Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. J Biol Chem 2005; 280(47):39474-39484.
287. Rowley JW, Oler A, Tolley ND, et al. Genome wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood 2011; 118(14):e101-111.
288. Piechulek T, Rehlen T, Walliser C, et al. Isozyme-specific stimulation of phospholipase C-gamma2 by Rac GTPases. J Biol Chem 2005; 280(47):38923-38931.
289. Pleines I, Elvers M, Strehl A, et al. Rac1 is essential for phospholipase C-gamma2 activation in platelets. Pflugers Arch 2009; 457(5):1173-1185.
290. Guidetti GF, Bernardi B, Consonni A, et al. Integrin alpha2beta1 induces phosphorylation-dependent and phosphorylation-independent activation of phospholipase C gamma2 in platelets: role of Src kinase and Rac GTPase. J Thromb Haemostasis 2009; 7(7):1200-1206.
291. Akbar H, Kim J, Funk K, et al. Genetic and pharmacologic evidence that Rac1 GTPase is involved in regulation of platelet secretion and aggregation. J Thromb Haemostasis 2007; 5(8):1747-1755.
292. Oda A, Miki H, Wada I, et al. WAVE/Scars in platelets. Blood 2005; 105(8):3141-3148.
293. Azuma T, Witke W, Stossel TP, et al. Gelsolin is a downstream effector of rac for fibroblast motility. EMBO J 1998; 17(5):1362-1370.
294. May RC. The Arp2/3 complex: a central regulator of the actin cytoskeleton. Cell Mol Life Sci 2001; 58(11):1607-1626.
295. Ridley A. Life at the leading edge. Cell 2011; 145(7):1012-1022.
296. Chang JC, Chang HH, Lin CT, et al. The integrin alpha6beta1 modulation of PI3 K and Cdc42 activities induces dynamic filopodium formation in human platelets. J Biomed Sci 2005; 12(6):881-898.
297. Pleines I, Eckly A, Elvers M, et al. Multiple alterations of platelet functions dominated by increased secretion in mice lacking Cdc42 in platelets. Blood 2010; 115(16):3364-3373.
298. Harper MT, Poole AW. Diverse functions of protein kinase C isoforms in platelet activation and thrombus formation. J Thromb Haemostasis 2010; 8(3):454-462.
299. Harper MT, Poole AW. Isoform-specific functions of protein kinase C: the platelet paradigm. Biochem Soc T 2007; 35(Pt 5):1005-1008.
300. Heemskerk JW, Harper MT, Cosemans JM, et al. Unravelling the different functions of protein kinase C isoforms in platelets. FEBS Lett 2011; 585(12):1711-1716.
301. Harper MT, Poole AW. Protein kinase Ctheta negatively regulates store-independent Ca2+ entry and phosphatidylserine exposure downstream of glycoprotein VI in platelets. J Biol Chem 2010; 285(26):19865-19873.
302. Harper MT, Poole AW. PKCtheta in platelet activation. Blood 2009; 114(2):489-491.
303. Pula G, Schuh K, Nakayama K, et al. PKCdelta regulates collagen-induced platelet aggregation through inhibition of VASP-mediated filopodia formation. Blood 2006; 108(13):4035-4044.
304. Gilio K, Harper MT, Cosemans JM, et al. Functional divergence of platelet protein kinase C (PKC) isoforms in thrombus formation on collagen. J Biol Chem 2010; 285(30):23410-23419.
305. Harper MT, Molkentin JD, Poole AW. Protein kinase C alpha enhances sodium-calcium exchange during store-operated calcium entry in mouse platelets. Cell Calcium 2010; 48(6):333-340.
306. Mundell SJ, Jones ML, Hardy AR, et al. Distinct roles for protein kinase C isoforms in regulating platelet purinergic receptor function. Mol Pharmacol 2006; 70(3):1132-1142.
307. Nagy B, Jr., Bhavaraju K, Getz T, et al. Impaired activation of platelets lacking protein kinase C-theta isoform. Blood 2009; 113(11):2557-2567.
308. Pears CJ, Thornber K, Auger JM, et al. Differential roles of the PKC novel isoforms, PKCdelta and PKCepsilon, in mouse and human platelets. PLoS One 2008; 3(11):e3793.
309. Buensuceso CS, Obergfell A, Soriani A, et al. Regulation of outside-in signaling in platelets by integrin-associated protein kinase C beta. J Biol Chem 2005; 280(1):644-653.
310. Soriani A, Moran B, de Virgilio M, et al. A role for PKCtheta in outside-in alpha(IIb)beta3 signaling. J Thromb Haemostasis 2006; 4(3):648-655.
311. Konopatskaya O, Gilio K, Harper MT, et al. PKCalpha regulates platelet granule secretion and thrombus formation in mice. J Clin Invest 2009; 119(2):399-407.
312. Konopatskaya O, Poole AW. Protein kinase C alpha: disease regulator and therapeutic target. Trends Pharmacol Sci 2010; 31(1):8-14.
313. Qiu Y, Kung HJ. Signaling network of the Btk family kinases. Oncogene 2000; 19(49):5651-5661.
314. Crosby D, Poole AW. Interaction of Bruton's tyrosine kinase and protein kinase Ctheta in platelets. Cross-talk between tyrosine and serine/threonine kinases. J Biol Chem 2002; 277(12):9958-9965.
315. Mukhopadhyay S, Ramars AS, Dash D. Bruton's tyrosine kinase associates with the actin-based cytoskeleton in activated platelets. J Cell Biochem 2001; 81(4):659-665.
316. Barry FA, Gibbins JM. Protein kinase B is regulated in platelets by the collagen receptor glycoprotein VI. J Biol Chem 2002; 277(15):12874-12878.
317. Yamaji S, Suzuki A, Kanamori H, et al. Possible role of ILK-affixin complex in integrin-cytoskeleton linkage during platelet aggregation. Biochem Bioph Res Co 2002; 297(5):1324-1331.
318. Tucker KL, Sage T, Stevens JM, et al. A dual role for integrin-linked kinase in platelets: regulating integrin function and alpha-granule secretion. Blood 2008; 112(12):4523-4531.
319. Walker TR, Watson SP. Synergy between Ca2+ and protein kinase C is the major factor in determining the level of secretion from human platelets. Biochem J 1993; 289(Pt 1):277-282.
320. Pfeffer S. Membrane domains in the secretory and endocytic pathways. Cell 2003; 112(4):507-517.
321. Seabra MC, Mules EH, Hume AN. Rab GTPases, intracellular traffic and disease. Trends Mol Med 2002; 8(1):23-30.
322. Fitzgerald ML, Reed GL. Rab6 is phosphorylated in thrombin-activated platelets by a protein kinase C-dependent mechanism: effects on GTP/GDP binding and cellular distribution. Biochem J 1999; 342(Pt 2):353-360.
323. Karniguian A, Zahraoui A, Tavitian A. Identification of small GTP-binding rab proteins in human platelets: thrombin-induced phosphorylation of rab3B, rab6, and rab8 proteins. Proc Natl Acad Sci USA 1993; 90(16):7647-7651.
324. Shirakawa R, Higashi T, Tabuchi A, et al. Munc13-4 is a GTP-Rab27-binding protein regulating dense core granule secretion in platelets. J Biol Chem 2004; 279(11):10730-10737.
325. Shirakawa R, Higashi T, Kondo H, et al. Purification and functional analysis of a Rab27 effector munc 13-4 using a semi-intact platelet dense-granule secretion assay. Meth Enzymol 2005; 403:778-788.
326. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 2003; 115(4):461-473.
327. Neeft M, Wieffer M, de Jong AS, et al. Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol Biol Cell 2005; 16(2):731-741.
328. Ren Q, Wimmer C, Chicka MC, et al. Munc13-4 is a limiting factor in the pathway required for platelet granule release and hemostasis. Blood 2010; 116(6):869-877.
329. Sollner T, Whiteheart SW, Brunner M, et al. SNAP receptors implicated in vesicle targeting and fusion. Nature 1993; 362(6418):318-324.
330. Marks MS. A Munc in the platelet granule works. Blood 2010; 116(6):864-865.
331. Ren Q, Ye S, Whiteheart SW. The platelet release reaction: just when you thought platelet secretion was simple. Curr Opin Hematol 2008; 15(5):537-541.
332. Guan R, Dai H, Rizo J. Binding of the Munc13-1 MUN domain to membrane-anchored SNARE complexes. Biochemistry 2008; 47(6):1474-1481.
333. Rizo J, Sudhof TC. Snares and Munc18 in synaptic vesicle fusion. Nat Rev Neurosci 2002; 3(8):641-653.
334. Houng A, Polgar J, Reed GL. Munc18-syntaxin complexes and exocytosis in human platelets. J Biol Chem 2003; 278(22):19627-19633.
335. Schraw TD, Crawford GL, Ren Q, et al. Platelets from Munc18c heterozygous mice exhibit normal stimulus-induced release. Thromb Haemostasis 2004; 92(4):829-837.
336. Schraw TD, Lemons PP, Dean WL, et al. A role for Sec1/Munc18 proteins in platelet exocytosis. Biochem J 2003; 374(Pt 1):207-217.
337. Polgar J, Lane WS, Chung SH, et al. Phosphorylation of SNAP-23 in activated human platelets. J Biol Chem 2003; 278(45):44369-44376.
338. Reed GL, Houng AK, Fitzgerald ML. Human platelets contain SNARE proteins and a Sec1p homologue that interacts with syntaxin 4 and is phosphorylated after thrombin activation: implications for platelet secretion. Blood 1999; 93(8):2617-2626.
339. Kasirer-Friede A, Moran B, Nagrampa-Orje J, et al. ADAP is required for normal alphaIIbbeta3 activation by VWF/GP Ib-IX-V and other agonists. Blood 2007; 109(3):1018-1025.